Vyndaqel
Named-patient access overview. Vyndaqel is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Vyndaqel (tafamidis meglumine) is transthyretin (TTR) stabiliser (oral) approved by the US FDA in May 2019 (US, ATTR-CM) for wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalisation. The drug is manufactured by Pfizer. India patients use the Central Drugs Standard Control Organization named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Vyndaqel
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Vyndaqel is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Vyndaqel in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Vyndaqel
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.